NCT01363427

Brief Summary

The purpose of this study is to identify prognostic parameters about efficacy of Mesalazine in recently diagnosed patients with Morbus Crohn by retrospective data collection.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
161

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2007

Typical duration for all trials

Geographic Reach
1 country

16 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2010

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

May 30, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 1, 2011

Completed
Last Updated

June 1, 2011

Status Verified

May 1, 2011

Enrollment Period

3.2 years

First QC Date

May 30, 2011

Last Update Submit

May 31, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Response to Mesalazine: measured by time to step up therapy

    12 to 48 months

Secondary Outcomes (1)

  • Identification and characterisation of the responding sub-population

    12 to 48 months

Study Arms (1)

Crohn's disease

Patients with initially diagnosed Crohn's disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Private practices

You may qualify if:

  • therapeutic need according to SPC
  • written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

Investigational Site, Ehrenfelsstraße 47

Berlin, Germany

Location

Investigational Site, Möllendorfstraße 111

Berlin, Germany

Location

Investigational Site, Graseggerstraße 105

Cologne, Germany

Location

Investigational Site, Münchner Straße 64

Dachau, Germany

Location

Investigational Site, Karlsbader Straße 7

Dinkelsbühl, Germany

Location

Investigational Site, Heiligengrabstraße 16

Hof, Germany

Location

Investigational Site, Am Tiefen Weg 2

Karlstadt am Main, Germany

Location

Investigational Site, Erdbeerfeld 8

Kiel-Altenholz, Germany

Location

Investigational Site, Hohenfelder Straße 20

Koblenz, Germany

Location

Investigational Site, Funkenburgstraße 19

Leipzig, Germany

Location

Investigational Site, Franz-Kail-Straße 2

Leverkusen, Germany

Location

Investigational Site, Bahnhofplatz 2

Mainz, Germany

Location

Investigational Site, Uferstraße 3

Minden, Germany

Location

Investigational Site, Hammer Straße 95

Münster, Germany

Location

Investigational Site, Weiltinger Str. 11

Nuremberg, Germany

Location

Investigational Site, Marktplatz 23

Rottenburg, Germany

Location

MeSH Terms

Conditions

Crohn Disease

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Study Officials

  • Clinical Development Support

    Ferring Pharmaceuticals

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 30, 2011

First Posted

June 1, 2011

Study Start

March 1, 2007

Primary Completion

May 1, 2010

Study Completion

July 1, 2010

Last Updated

June 1, 2011

Record last verified: 2011-05

Locations